Alphatec EVP Sells 37,000 Shares in Rule‑10b5‑1 Plan Amid Steady Insider Selling Trend

Insider Selling by EVP of People & Culture Signals a Shift

Alphatec Holdings’ EVP of People & Culture, Craig Hunsaker, sold 37,358 shares on February 3, 2026 under a Rule 10b5‑1 trading plan. The transaction, priced at an average of $14.71, reduces his stake from 1,173,025 to 1,135,667 shares. The sale is part of a broader pattern: Hunsaker has sold a total of 132,942 shares in the past year, most recently in December 2025 when he off‑loaded 32,584 shares at $20.84. His previous sale on October 31, 2025, involved 100,000 shares at $19.95, and a 2025 April purchase of 21,751 shares at market price. The cumulative effect is a net divestiture of roughly 9 % of his holding, aligning with the company’s overall trend of insider selling.

What the Sale Means for Investors

The timing of the sale—just after a 7.93 % weekly decline and a 33.73 % monthly drop—suggests that insiders are taking profits as the stock retraces from a 52‑week high of $23.29 to a near $14 market. Hunsaker’s sale is modest relative to the total outstanding shares, but it adds to a wave of insider disposals that included the CEO, COO, and CFO in December 2025. When insider sales concentrate in a short period, analysts often interpret them as a signal that management anticipates a near‑term correction or that liquidity needs are pressing. However, Hunsaker’s transaction was executed under a pre‑established plan, which can mitigate the “negative signal” perception and indicates that the sale may be driven more by personal cash‑flow management than by a pessimistic view of Alphatec’s prospects.

Insider Activity in Context

Alphatec’s stock remains a high‑beta play in the healthcare equipment space, with a negative P/E of –14 and a price‑to‑book ratio of 190.67—figures that underscore the company’s ongoing profitability challenges. Insider sales have increased in the last quarter, but the overall insider ownership percentage has barely dipped below 10 %. Investors should note that the bulk of these sales were conducted at market prices that were largely above the 52‑week low, suggesting that insiders are not dumping on a steep decline but are instead normalizing their positions. The recent social‑media sentiment (+10) and moderate buzz (10.64 %) indicate that the market’s attention is relatively muted; thus, the impact of the sale on short‑term price movement is likely limited.

Craig Hunsaker: A Profile Based on Trading Patterns

Hunsaker has been a long‑term shareholder, holding 1.65 million shares as of April 2025 before the first purchase in 2025. His trading history reveals a conservative approach: he buys when the price dips (e.g., April 1, 2025 purchase) and sells when the share price rises (e.g., October 31 and December 10 sales). He rarely trades in large blocks; each sale ranges from 10,000 to 100,000 shares, a pattern consistent with a Rule 10b5‑1 plan aimed at liquidity rather than speculation. Moreover, Hunsaker’s transactions have been executed at market price with no reported insider intent to influence the share price, suggesting a prudent, compliance‑focused trading strategy. For investors, this profile implies that Hunsaker is unlikely to engage in aggressive short‑term trading that would destabilize the stock; instead, his activity reflects routine portfolio management.

Outlook for Alphatec

With the company’s market cap hovering around $2.18 billion and a negative earnings metric, Alphatec remains a value play for investors willing to weather volatility. Insider sales, while a point of watch, are part of a broader trend of normalizing ownership stakes. If the company can sustain its revenue streams from spine‑surgery solutions and leverage its high‑margin product lines, the stock may rebound from the current $14.05 level. Until then, investors should monitor insider activity as a gauge of confidence while keeping an eye on earnings releases and product pipeline updates, which will ultimately drive long‑term valuation.